EyePoint to Report Fourth Quarter and Full-Year 2024 Financial Results on March 5, 2025
EyePoint Pharmaceuticals (NASDAQ: EYPT) has scheduled its fourth quarter and full-year 2024 financial results announcement for March 5, 2025. The company, which focuses on developing innovative therapeutics for serious retinal diseases, will host a conference call and webcast at 8:30 a.m. ET.
Investors and interested parties can access the live conference call through a registration link, while a live audio webcast will be available through the Investors section of EyePoint's website. A replay of the webcast will be accessible on the corporate website after the call concludes.
EyePoint Pharmaceuticals (NASDAQ: EYPT) ha programmato l'annuncio dei risultati finanziari del quarto trimestre e dell'intero anno 2024 per il 5 marzo 2025. L'azienda, che si concentra sullo sviluppo di terapie innovative per gravi malattie retiniche, ospiterà una conferenza telefonica e una webcast alle 8:30 a.m. ET.
Gli investitori e le parti interessate possono accedere alla conferenza telefonica dal vivo tramite un link di registrazione, mentre una webcast audio dal vivo sarà disponibile nella sezione Investitori del sito web di EyePoint. Una registrazione della webcast sarà accessibile sul sito aziendale dopo la conclusione della chiamata.
EyePoint Pharmaceuticals (NASDAQ: EYPT) ha programado el anuncio de los resultados financieros del cuarto trimestre y del año completo 2024 para el 5 de marzo de 2025. La compañía, que se centra en desarrollar terapias innovadoras para enfermedades retinianas graves, llevará a cabo una conferencia telefónica y una transmisión web a las 8:30 a.m. ET.
Los inversores y partes interesadas pueden acceder a la conferencia telefónica en vivo a través de un enlace de registro, mientras que una transmisión de audio en vivo estará disponible en la sección de Inversores del sitio web de EyePoint. Una repetición de la transmisión estará accesible en el sitio web corporativo después de que finalice la llamada.
EyePoint Pharmaceuticals (NASDAQ: EYPT)는 2025년 3월 5일에 2024년 4분기 및 연간 재무 결과 발표를 예정하고 있습니다. 심각한 망막 질환을 위한 혁신적인 치료제를 개발하는 데 중점을 두고 있는 이 회사는 동부 표준시 기준 오전 8시 30분에 전화 회의 및 웹캐스트를 개최할 예정입니다.
투자자 및 이해관계자는 등록 링크를 통해 실시간 전화 회의에 접근할 수 있으며, EyePoint 웹사이트의 투자자 섹션을 통해 실시간 오디오 웹캐스트도 이용할 수 있습니다. 회의가 끝난 후 기업 웹사이트에서 웹캐스트의 재생이 가능합니다.
EyePoint Pharmaceuticals (NASDAQ: EYPT) a prévu l'annonce de ses résultats financiers du quatrième trimestre et de l'année complète 2024 pour le 5 mars 2025. L'entreprise, qui se concentre sur le développement de thérapies innovantes pour des maladies rétiniennes graves, organisera une conférence téléphonique et un webinaire à 8h30 ET.
Les investisseurs et les parties intéressées peuvent accéder à la conférence téléphonique en direct via un lien d'inscription, tandis qu'un webinaire audio en direct sera disponible dans la section Investisseurs du site web d'EyePoint. Une rediffusion du webinaire sera accessible sur le site corporatif après la fin de l'appel.
EyePoint Pharmaceuticals (NASDAQ: EYPT) hat die Bekanntgabe der finanziellen Ergebnisse für das vierte Quartal und das gesamte Jahr 2024 für den 5. März 2025 angesetzt. Das Unternehmen, das sich auf die Entwicklung innovativer Therapeutika für schwere Netzhauterkrankungen konzentriert, wird um 8:30 Uhr ET eine Telefonkonferenz und ein Webcast veranstalten.
Investoren und interessierte Parteien können über einen Registrierungslink auf die Live-Telefonkonferenz zugreifen, während ein Live-Audio-Webcast über den Investorenbereich der EyePoint-Website verfügbar sein wird. Eine Wiederholung des Webcasts wird nach Abschluss der Konferenz auf der Unternehmenswebsite zugänglich sein.
- None.
- None.
WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 5, 2025 to report its fourth quarter and full-year 2024 financial results and highlight recent corporate developments.
To access the live conference call, please register using the audio conference link: https://register.vevent.com/register/BI804e9c71d61543cab2c16376caae4936. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharma.com. A webcast replay will also be available on the corporate website at the conclusion of the call.
About EyePoint
EyePoint (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery. The Company’s lead product candidate, DURAVYU™ is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E™. Supported by robust safety and efficacy data to date, DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD), the leading cause of vision loss among people 50 years of age and older in the United States, and recently completed a Phase 2 clinical trial in diabetic macular edema (DME). Based on positive Phase 2 results from the VERONA clinical trial in DME, EyePoint anticipates meeting with U.S. and ex-U.S. regulatory agencies in the second quarter of 2025 to confirm plans for a pivotal program.
Pipeline programs include EYP-2301, a TIE-2 agonist, razuprotafib, formulated in Durasert E™ to potentially improve outcomes in serious retinal diseases. The proven Durasert® drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products in multiple disease indications. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.
DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
Investors:
Christina Tartaglia
Precision AQ
Direct: 212-698-8700
christina.tartaglia@precisionaq.com
Media Contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com
FAQ
When will EyePoint Pharmaceuticals (EYPT) release Q4 and FY 2024 earnings?
How can investors access EYPT's Q4 2024 earnings call?
Will there be a replay available for EyePoint's Q4 2024 earnings call?
What is the focus of EyePoint Pharmaceuticals' business?
